Thermo Fisher Scientific and NanoPin Technologies have partnered up to develop sensitive clinical assays for infectious diseases. NanoPin has proprietary antibody-conjugated nanoparticles which are specifically adapted to antigen peptides that are only present in the bloodstream when the targeted disease is active. NanoPin will advance their blood-based infectious disease detection technology by using Thermo Fisher's advanced liquid chromatography-mass spectrometry technology. 

This will enable healthcare providers to reduce time to results, determine infection stage and monitor patient response to prescribed treatment. The quantified information gleaned from the combined technology will support clinical decision-making and the provision of personalized patient care unique to their disease state.